---
audienceLevel: patient
cancerTypes:
- general
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- treatment
title: Recombinant Human Papillomavirus (HPV) Bivalent Vaccine - NCI
url: https://www.cancer.gov/about-cancer/treatment/drugs/recombinant-hpv-bivalent-vaccine
version: v1
---

# Recombinant Human Papillomavirus (HPV) Bivalent Vaccine - NCI

# Recombinant Human Papillomavirus (HPV) Bivalent Vaccine

Placeholder slot

(ree-KOM-bih-nunt HYOO-mun PA-pih-LOH-muh-VY-rus by-VAY-lent vak-SEEN)

The HPV bivalent vaccine protects against infection with high-risk HPV types 16 and 18, which cause most precancers and cancers of the cervix.

US Brand Name(s)

Cervarix

FDA Approved

No longer available in the U.S.

## Use in Cancer

The HPV bivalent vaccine is used in females aged 10 to 25 years to prevent:

- **[Cervical cancer](/Common/PopUps/popDefinition.aspx?id=444973&version=Patient&language=English).**
- **[Lesions](/Common/PopUps/popDefinition.aspx?id=46324&version=Patient&language=English)** that sometimes lead to cervical cancer.

The recombinant HPV bivalent vaccine is no longer available in the United States. It is still used in other countries.

## More About Recombinant Human Papillomavirus (HPV) Bivalent Vaccine

[Definition from the NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/442270) - Detailed scientific definition and other names for this drug.

MedlinePlus Information on [Human Papillomavirus (HPV) Vaccine](https://medlineplus.gov/druginfo/meds/a610014.html) - A lay language summary of important information about this drug that may include the following:

- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

## Research Results and Related Resources

[More Evidence that One HPV Vaccine Dose Protects against Cancer-Causing Infections](https://www.cancer.gov/news-events/cancer-currents-blog/2022/cervical-cancer-hpv-vaccine-one-dose-kenya)

[HPV and Cancer](https://www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/hpv-and-cancer)

[Despite Proven Safety of HPV Vaccines, More Parents Have Concerns](https://www.cancer.gov/news-events/cancer-currents-blog/2021/hpv-vaccine-parents-safety-concerns)

[Human Papillomavirus (HPV) Vaccines](https://www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/hpv-vaccine-fact-sheet)

[Single Dose of HPV Vaccine Yields Long-Term Protection from Many Cancer-Causing Types](https://www.cancer.gov/news-events/cancer-currents-blog/2020/hpv-vaccine-single-dose-long-term-protection)

[HPV Vaccine May Provide Men with “Herd Immunity” against Oral HPV Infections](https://www.cancer.gov/news-events/cancer-currents-blog/2019/men-oral-hpv-infection-vaccine-herd-immunity)

[The HPV Vaccine: Increasing the Use of an Important Cancer Prevention Tool](https://www.cancer.gov/news-events/cancer-currents-blog/2018/hpv-vaccine-presidents-cancer-panel-improving-uptake)

## Clinical Trials Accepting Patients

[Find Clinical Trials for Recombinant Human Papillomavirus Bivalent Vaccine](https://www.cancer.gov/research/participate/clinical-trials/intervention/C48395) - Check for trials from NCI's list of cancer clinical trials now accepting patients.
